Published: 30, Sep 2026

AI in Dermatology Market

AI in Dermatology Market Size, Share and Analysis By Component (Software, Services, Hardware), By Technology Type (Cancer Detection Software, Remote Consultation Platforms, Dermoscopic Imaging Systems, AI Skin Analytics), By Deployment Mode (Cloud-Based, Device-Based, On-Premises), By End User (Dermatology Clinics, Hospitals, Direct-to-Consumer, Pathology Centers, Cosmetic Companies), and Regional Forecast Till 2034.

Download Free Sample

Market Size (2025):

USD 8.5 Billion

CAGR (2026–2034):

15.8%

Report Pages:

160-170

Market Tables:

50-60

Table of Content

Get a free sample of this report

Overview

The global AI in Dermatology Market was valued at USD 8.5 billion in 2025 and is projected to reach USD 31.7 billion by 2034, growing at a CAGR of 15.8% during the forecast period (2026-2034). The market growth is driven by rising demand for AI-powered skin diagnosis, increasing prevalence of dermatological conditions, growing adoption of teledermatology, advances in medical imaging and machine learning. The market is shifting from isolated pilot deployments of AI lesion classifiers toward infrastructure-grade procurement embedded in routine clinical and retail-health workflows. Government initiatives such as the U.S. FDA's expanding use of the De Novo and 510(k) pathways for AI-enabled dermatology devices, and the UK National Health Service's continued funding of AI-based skin cancer triage pathways through NHS England's Cancer Programme, are reinforcing clinical adoption and creating regulatory precedent for further AI dermatology device clearances. By region, North America held the largest share of the market in 2025, supported by a dense concentration of dermatology specialists, an active FDA clearance environment for AI-enabled skin lesion analysis devices, and early payer engagement with AI-assisted triage. Asia-Pacific is expected to be the fastest-growing region during the forecast period, driven by expanding teledermatology adoption, rising skin cancer and skincare awareness, and growing investment in digital health infrastructure across China, India, Japan, and South Korea.

Market Size & Share

CAGR (2026–2034):

Market Snapshot

Study Period:	2021-2034
Market Size in 2025:	USD 8.5 Billion
Market Size in 2026:	USD 9.8 Billion
Market Size by 2034:	USD 31.7 Billion
Unit Value:	USD Billion
Projected CAGR:	15.8% (2026-2034)
Largest Region:	North America
Fastest-Growing Region:	Asia-Pacific
Fastest-Growing Product/Technology Type:	Remote Consultation Platforms

Market Dynamics

KEY MARKET TREND:

AI-Powered Total-Body and Multi-Spectral Imaging Becoming Standard of Care in Dermatology

Deep-learning lesion classifiers are moving from limited pilot studies into routine clinical deployment as health systems gain confidence in triage-grade sensitivity for melanoma and non-melanoma skin cancers.
Total-body photography combined with AI-driven lesion change-tracking is being adopted to support longitudinal monitoring of high-risk patients rather than single-visit assessment alone.
Software vendors and imaging-hardware providers are increasingly partnering to embed AI classification directly into dermoscopy and total-body imaging systems, shortening the path from image capture to clinical decision.
The UK's National Health Service continued to expand AI-based skin cancer triage pathways, such as Skin Analytics' DERM system, across additional NHS trusts through NHS England Cancer Programme funding rounds in 2025-2026, reflecting institutional validation of AI dermatology triage at national scale.

KEY MARKET DRIVER:

Rising Global Burden of Skin Cancer and Persistent Dermatologist Shortages is the Key Driver

The increasing global incidence of skin cancer and chronic inflammatory skin conditions is expanding the pool of patients requiring timely dermatologic assessment, straining existing specialist capacity.
A persistent shortage of practicing dermatologists relative to patient demand, particularly in rural and underserved regions, is prompting health systems to adopt AI-assisted triage tools that allow non-specialists to make more informed referral decisions.
Rising smartphone penetration and telehealth adoption are lowering the barrier to AI-assisted skin assessment, enabling remote and point-of-care diagnosis outside traditional dermatology clinics.
The Skin Cancer Foundation, a U.S.-based nonprofit organization, projected that newly diagnosed melanoma cases in the United States would rise by approximately 10.6% during the year, intensifying demand for tools that support earlier and more accurate skin cancer detection.

KEY MARKET OPPORTUNITY:

Expansion of AI-Enabled Primary Care and Retail-Health Teledermatology Access Creates Significant Opportunity

Integration of AI dermatology tools into primary care settings, following handheld point-of-care device models, creates an opportunity to extend specialist-grade triage capability to non-specialist clinicians.
Retail and consumer health platforms are opening new distribution channels for AI-assisted dermatology services, extending reach beyond traditional hospital and clinic settings.
Growing investor and corporate interest in dermatopathology AI is creating opportunities for deeper integration between diagnostic imaging, pathology, and downstream treatment planning.
Teladoc Health expanded its dermatology service through Walmart's Better Care Services platform, enabling consumers to upload skin images for AI-supported, board-certified dermatologist review within 24 hours at a flat cash-pay fee, illustrating growing retail-health integration of AI dermatology services.

AI in Dermatology Market Size, 2025-2034 (USD Billion)

Segmentation Analysis

Analysis by Component

Software held the largest market share in 2025 because AI dermatology adoption has been led by cloud-hosted and on-device lesion classification algorithms, clinical decision-support engines, and consumer skin-analytics engines that can be layered onto existing imaging hardware at comparatively low incremental cost. Software platforms benefit from faster iteration cycles, easier multi-site deployment, and recurring subscription revenue models that make them the primary entry point for both clinical and consumer AI dermatology adoption.

Services is projected to grow at the fastest CAGR during the forecast period, supported by rising demand for AI-supported teledermatology consultation services, algorithm validation and regulatory-support services, and managed deployment services as health systems and retail-health platforms scale AI-assisted dermatology programs across larger patient populations and multiple care settings.

Component categories include

· Software (Dominating Segment)

· Services (Highest CAGR Segment)

· Hardware

Analysis by Technology Type

Cancer Detection Software held the largest market share in 2025, supported by the concentration of AI development, clinical validation, and regulatory clearance activity around melanoma and non-melanoma skin cancer classification. Skin cancer represents the highest-stakes and most clinically validated use case for AI in dermatology, giving this category the deepest base of commercially deployed, regulator-reviewed products.

Remote Consultation Platforms are projected to grow at the fastest CAGR during the forecast period, driven by expanding retail-health partnerships, growing consumer comfort with remote care, and continued shortages of in-person dermatology appointment capacity that are pushing both patients and health systems toward AI-supported remote triage and consultation models.

Technology Type categories include

· Cancer Detection Software (Dominating Segment)

· Remote Consultation Platforms (Highest CAGR Segment)

· Dermoscopic Imaging Systems

· AI Skin Analytics

Analysis by Deployment Mode

Cloud-Based deployment held the largest market share in 2025, supported by lower upfront infrastructure requirements, easier multi-site and multi-device scaling, and the ability for vendors to continuously update classification models without requiring on-site hardware changes across dermatology clinics and hospital networks. Growing adoption of cloud infrastructure among healthcare providers is also enabling remote collaboration, centralized model management, and faster deployment of new AI capabilities.

Device-Based deployment is projected to grow at the fastest CAGR during the forecast period, supported by growing demand for point-of-care devices that can deliver a result without requiring continuous connectivity, which is particularly valuable in primary care and rural settings where reliable broadband access cannot be assumed. Integration of AI algorithms into handheld imaging and diagnostic systems is also improving rapid skin assessment and enabling more efficient clinical decision-making at the point of care.

Deployment Mode categories include

· Cloud-Based (Dominating Segment)

· Device-Based (Highest CAGR Segment)

· On-Premises

Analysis by End User

Dermatology Clinics held the largest market share in 2025, reflecting the concentration of specialist-led skin lesion evaluation, established imaging infrastructure, and existing workflows into which AI decision-support and lesion-tracking tools can be integrated with comparatively limited disruption to clinical practice. Growing use of digital dermoscopy and AI-assisted image analysis is also supporting more consistent evaluation and follow-up of dermatological conditions.

Hospitals are projected to grow at the fastest CAGR during the forecast period, supported by growing institutional investment in AI-enabled dermatopathology, integration of AI triage into hospital-based cancer pathways, and academic centers' role in conducting the clinical validation studies required for broader regulatory clearance and adoption. Increasing availability of connected imaging systems and digital pathology platforms is also facilitating the deployment of AI-based screening, diagnosis, and patient monitoring solutions across hospital departments.

End User categories include

· Dermatology Clinics (Dominating Segment)

· Hospitals (Highest CAGR Segment)

· Direct-to-Consumer

· Pathology Centers

· Cosmetic Companies

By Region

AI In Dermatology Market Regional Analysis

AI In Dermatology Market Share 2025, (CAGR)

Regional Analysis

North America held the largest market share in 2025, supported by a dense concentration of board-certified dermatologists, well-established dermatology clinic and hospital networks, and an active U.S. FDA clearance environment for AI-enabled skin lesion analysis devices such as handheld spectroscopy-based skin cancer detection tools. The region benefits from early payer engagement with AI-assisted triage programs, growing retail-health partnerships extending dermatology access through pharmacy and telehealth channels, and a competitive landscape of both specialist AI dermatology vendors and large consumer health and beauty companies embedding AI skin diagnostics into their platforms. The United States accounts for the substantial majority of regional demand, supported by ongoing regulatory clearance activity and ongoing investment in AI-enabled dermatopathology.

Asia-Pacific is projected to grow at the fastest CAGR during the forecast period, driven by expanding teledermatology adoption across China, India, Japan, and South Korea, rising skin cancer and skincare awareness among growing middle-class populations, and increasing government and private investment in digital health infrastructure. China and India are witnessing rapid growth in smartphone-based teledermatology and AI skin-analytics platforms, supported by large addressable populations with limited access to in-person dermatology specialists, while Japan and South Korea maintain strong positions in AI-enabled cosmetic and aesthetic skin-analytics technology adoption linked to their established skincare and beauty industries.

Countries and Region covered

North America (Dominating Region)

o United States

o Canada

o Mexico

Europe

o Germany

o United Kingdom

o France

o Italy

o Rest of Europe

Asia Pacific (Fastest Growing Region)

o China

o India

o Japan

o South Korea

o Rest of Asia Pacific

Latin America

o Brazil

o Chile

o Rest of Latin America

Middle East & Africa

o Saudi Arabia

o U.A.E.

o Rest of Middle East & Africa

Market Share

The market is fragmented, characterized by a large number of specialized AI dermatology start-ups operating alongside diversified imaging-hardware manufacturers and clinical decision-support providers. Key players include DermaSensor, Inc., Skin Analytics Ltd, SkinVision B.V., FotoFinder Systems GmbH, Canfield Scientific, Inc., Logical Images, Inc. (VisualDx), MetaOptima Technology Inc., Legit.Health, Piction Health, Skinive B.V., Miiskin Group ApS, SkinIO, Inc., Haut.AI OÜ, Perfect Corp., and PathAI, Inc. Key success factors include regulatory clearance track record, clinical validation depth, integration with existing dermatology and primary care workflows, and the ability to scale across both clinical and consumer channels. Leading companies are prioritizing continued clinical validation and regulatory clearance, integration partnerships with health systems, retail-health platforms, and imaging-hardware providers, and strategic investment in dermatopathology and multi-condition AI capabilities, as reflected in Roche's May 2026 definitive merger agreement to acquire PathAI for an upfront purchase price of USD 750 million plus milestone payments of up to USD 300 million.

Key Players

· DermaSensor, Inc. (United States)

· Skin Analytics Ltd (United Kingdom)

· SkinVision B.V. (Netherlands)

· FotoFinder Systems GmbH (Germany)

· Canfield Scientific, Inc. (United States)

· Logical Images, Inc. (VisualDx) (United States)

· MetaOptima Technology Inc. (Canada)

· AI Labs Group S.L. (Spain)

· Piction Health, Inc. (United States)

· Skinive B.V. (Netherlands)

· Miiskin Group ApS (Denmark)

· SkinIO, Inc. (United States)

· Haut.AI OÜ (Estonia)

· Perfect Corp. (Taiwan)

· PathAI, Inc. (United States)

Recent Market Developments

November 2025: Haut.AI introduced Face Analysis 3.0, an advanced AI skin-assessment engine capable of distinguishing between fine and deep wrinkles and separating freckles from sunspots, aimed at delivering more granular, dermatologist-comparable skin evaluation for skincare and cosmetics partners.
March 2026: SkinVision announced a research collaboration with the Mayo Clinic to conduct an FDA-required pivotal trial evaluating its AI-based skin spot assessment mobile application, representing a key milestone on the company's pathway to U.S. regulatory clearance.
May 2026: Roche announced a definitive merger agreement to acquire dermatopathology AI provider PathAI for up to USD 1.05 billion, linking AI-based dermatopathology image analysis with Roche's large-scale diagnostics distribution network and signaling a shift of AI dermatology tools from pilot use toward infrastructure-grade procurement.
June 2026: Skin Analytics launched DERM Zero, a Class III regulated AI medical device that enables autonomous clinical-grade skin cancer assessment using a standard smartphone; the technology is deployed across 24 NHS hospitals, has assessed over 230,000 patients, and detected more than 20,000 cancers.

Frequently Asked Questions

What is the AI in Dermatology Market?

The AI in Dermatology Market covers artificial intelligence and machine learning-enabled software, hardware, and services used to detect, diagnose, monitor, and manage skin conditions, including skin cancer, inflammatory dermatoses, and cosmetic skin concerns.